.avif)
.avif)
Coherus Biosciences Email Format
Biotechnology Research
・
201-500 employees
・
Redwood City, CA, USA
Coherus Biosciences is a commercial-stage oncology company developing and marketing innovative cancer therapies, including its approved PD-1 inhibitor and a pipeline targeting liver, lung, and head and neck cancers.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@coherus.com
Company Overview
Industry
Biotechnology Research
Founded
2010
Headquarters
Redwood City, CA, USA
Revenue
$25M-$50M
FUNDING Stage
Public
Website
Key Executives
Dennis M. Lanfear (President & Chief Executive Officer), Bryan McMichael (Chief Financial Officer), Richard L. Hameister (Chief Technical Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Coherus Biosciences?
Coherus Biosciences uses the firstinitiallast format on coherus.com, so Jane Smith would be jsmith@coherus.com.
What FDA-approved medicine does Coherus Biosciences currently sell?
Coherus Biosciences markets LOQTORZI (toripalimab-tpzi), an FDA-approved PD-1 therapy for cancer. The company has fully transitioned from biosimilars and now focuses on immuno-oncology as Coherus Oncology.
How many people work at Coherus Biosciences?
Coherus Biosciences has approximately 212 employees and is headquartered in Redwood City, CA. You can use Clay to build a targeted list of contacts at the company and verify their email addresses before reaching out.
Who leads Coherus Biosciences as CEO?
Dennis M. Lanfear serves as President and Chief Executive Officer of Coherus Biosciences. Bryan McMichael holds the role of Chief Financial Officer and Richard L. Hameister serves as Chief Technical Officer.
What immuno-oncology pipeline candidates is Coherus Biosciences developing?
Coherus Biosciences is advancing three clinical-stage immuno-oncology candidates: toripalimab-tpzi targeting PD-1, tagmokitug targeting CCR8, and casdozokitug targeting IL-27, all aimed at overcoming immune resistance in cancer.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating